Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Battaglin

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Cancers|May 28, 2020
<i>WRN</i>-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic PhenotypeKai Zimmer, Alberto Puccini, Joanne Xiu, et al.
BMC Cancer|January 27, 2018
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patientsFrancesca Battaglin, Marta Schirripa, Federica Buggin, et al.
Oncogene|January 17, 2023
Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directionsPriya Jayachandran, Francesca Battaglin, Carly Strelez, et al.
Cancer|July 15, 2017
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancerSatoshi Okazaki, Marta Schirripa, Fotios Loupakis, et al.
Oncogene|May 26, 2022
Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targetsAlberto Puccini, Kelsey Poorman, Fabio Catalano, et al.
European Journal of Cancer (Oxford, England : 1990)|April 20, 2020
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trialsMartin D Berger, Yan Ning, Sebastian Stintzing, et al.
The Oncologist|July 7, 2016
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal CancerRoberto Moretto, Chiara Cremolini, Daniele Rossini, et al.
Ebiomedicine|July 14, 2019
Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor AElke Burgermeister, Francesca Battaglin, Fagr Eladly, et al.
NPJ Precision Oncology|September 30, 2024
Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancerJingyuan Wang, Joanne Xiu, Francesca Battaglin, et al.
Molecular Cancer Therapeutics|October 10, 2020
Molecular Characterization of Appendiceal Goblet Cell CarcinoidHiroyuki Arai, Yasmine Baca, Francesca Battaglin, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Cancers|May 28, 2020
<i>WRN</i>-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic PhenotypeKai Zimmer, Alberto Puccini, Joanne Xiu, et al.
BMC Cancer|January 27, 2018
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patientsFrancesca Battaglin, Marta Schirripa, Federica Buggin, et al.
Oncogene|January 17, 2023
Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directionsPriya Jayachandran, Francesca Battaglin, Carly Strelez, et al.
Cancer|July 15, 2017
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancerSatoshi Okazaki, Marta Schirripa, Fotios Loupakis, et al.
Oncogene|May 26, 2022
Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targetsAlberto Puccini, Kelsey Poorman, Fabio Catalano, et al.
European Journal of Cancer (Oxford, England : 1990)|April 20, 2020
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trialsMartin D Berger, Yan Ning, Sebastian Stintzing, et al.
The Oncologist|July 7, 2016
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal CancerRoberto Moretto, Chiara Cremolini, Daniele Rossini, et al.
Ebiomedicine|July 14, 2019
Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor AElke Burgermeister, Francesca Battaglin, Fagr Eladly, et al.
NPJ Precision Oncology|September 30, 2024
Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancerJingyuan Wang, Joanne Xiu, Francesca Battaglin, et al.
Molecular Cancer Therapeutics|October 10, 2020
Molecular Characterization of Appendiceal Goblet Cell CarcinoidHiroyuki Arai, Yasmine Baca, Francesca Battaglin, et al.
Pageof 9